Mechanism of Action Study
Understanding How Your Compound Works, Not Just That It Works
Once a hit or lead is validated through binding and activity assays, the next question is mechanistic: how, exactly, does it produce its pharmacological effect?
WuXi Biology and Testing’s mechanism of action (MOA) services elucidate the molecular mechanisms by which compounds modulate their biological targets. Depending on the target class and therapeutic modality, these profiling studies may include biochemical enzyme kinetics, receptor pharmacology, protein-protein interaction analysis, and biophysical target engagement. Together, these approaches provide deep insight into potency, selectivity, reversibility, binding kinetics, mode of inhibition, and downstream phenotypic responses.
By integrating biochemical assays with orthogonal biophysical and structural methods, MOA profiling provides the mechanistic understanding needed to optimize compounds, prioritize chemical series, and reduce translational development risk.
Determining Mechanism of Action Through Enzyme Kinetics
Compounds with similar potency can operate through fundamentally different mechanisms, and these differences often determine efficacy, selectivity, dosing strategy, and safety profile. Our teams use classical and advanced kinetic approaches to characterize inhibitor behavior at the molecular level.
- Baseline kinetic characterization: determination of enzyme activity, reaction rates, Km, and Vmax.
- Substrate–inhibitor titration experiments: systematic variation of substrate and inhibitor concentrations to distinguish competitive, noncompetitive, uncompetitive, and mixed inhibition mechanisms.
- Ki determination: quantitative measurement of inhibitor affinity independent of assay conditions, enabling comparison across chemical series and target classes.
- Mechanistic modeling: kinetic analysis to understand catalytic modulation and support structure–activity relationship (SAR) campaigns.
These studies help medicinal chemistry teams understand not only whether a molecule works, but how it modulates its target.
Reversibility, Time Dependence, and Binding Kinetics
Whether an inhibitor reaches rapid equilibrium or exhibits time-dependent binding, and whether its effect reverses upon compound washout, are critical mechanistic questions with direct implications for PK/PD modeling and safety profiles.
We evaluate time-dependent inhibition and reversibility as a standard part of MOA profiling, distinguishing rapidly reversible inhibitors from slow-binding or irreversible covalent ones. These kinetic parameters provide essential insight into target residence time, dosing frequency, and overall therapeutic windows.
Selectivity Profiling Across Kinase and Enzyme Panels
Mechanistic profiling extends beyond a single target. Understanding selectivity across related enzymes is essential to identify off-target liabilities and drive lead optimization.
- Panel profiling technologies: microfluidic mobility shift (Caliper), Kinase-Glo Plus, ADP-Glo, HTRF, TR-FRET, and complementary biochemical platforms.
- Flexible screening strategies: single-concentration percent inhibition, full dose–response curves, and rigorous IC₅₀ determination.
- SAR support: rapid turnaround and weekly screening schedules to accelerate Design-Make-Test-Analyze cycles.
- Library-scale capabilities: high-throughput evaluation of individual compounds or extensive chemical series.
Our representative kinase panels can evaluate compounds against more than 30 targets within one to two weeks, delivering actionable selectivity data to medicinal chemistry teams.
MOA Studies Across Biochemical Target Classes
Mechanism-of-action studies support a broad spectrum of biochemical targets, therapeutic areas, and modalities.
- Kinases: MAPK, AKT/PKB, JAK, IKK, and cell-cycle signaling pathways.
- Phosphatases, ATPases, and GTPases, including KRAS-associated mechanisms.
- Proteases, polymerases, and metabolic enzymes (e.g., Dehydrogenases and reductases).
- Epigenetic targets: histone methyltransferases (HMTs), demethylases (KDMs), histone deacetylases (HDACs), and bromodomains.
- Protein–protein interactions and ligand–receptor systems.
- Emerging modalities: bifunctional molecules (e.g., PROTAC, RIPTAC, molecular glues), covalent inhibitors, etc.
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
You May Also Be Interested In
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Frequently Asked Questions
An MOA (mechanism-of-action) study characterizes how a compound produces its effect on a validated target to produce the desired pharmacological effect. Depending on the target class, MOA studies may include enzyme kinetics, receptor pharmacology, protein–protein interaction analysis, binding kinetics, target engagement, or selectivity profiling. These studies typically follow binding and activity assays and provide the mechanistic insight needed to guide hit-to-lead optimization, lead optimization, and candidate selection.
An activity assay quantifies whether and how potently a compound modulates its target's function. A MoA study goes further, elucidating exactly how that modulation occurs mechanistically: e.g., competitive vs. allosteric, reversible vs. irreversible, or highly selective vs. broadly active.
Most discovery programs use activity data to triage and rank hits, then deploy MoA profiling to characterize the most promising leads in depth.
These describe how an inhibitor interacts with an enzyme relative to its substrate. Competitive inhibitors compete with substrate for the same binding site; non-competitive inhibitors bind elsewhere and reduce activity regardless of substrate concentration; uncompetitive inhibitors bind only to the enzyme-substrate complex. Substrate-inhibitor titration experiments distinguish between these mechanisms.
Reversible inhibitors achieve rapid equilibrium and dissociate upon drug clearance, while time-dependent (or irreversible covalent) inhibitors can drive prolonged target inactivation that persists after compound washout. This kinetic distinction has direct implications for clinical PK/PD modeling, target residence time, and overall therapeutic windows.
Our platform supports kinases, phosphatases, ATPases and GTPases (including KRAS), polymerases, dehydrogenases/reductases, proteases, epigenetic targets (HMT, KDM, HDAC, bromodomains), and protein-protein interactions.
Typical turnaround for kinase selectivity profiling is 1-2 weeks, with weekly screening service available to support ongoing SAR. Turnaround for broader mechanism-of-inhibition characterization (kinetics, reversibility, time-dependence) will depend on the specific study design."